# Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Canonical URL: https://biopharmsignal.com/news/XGN/exagen-announces-publication-of-systematic-review-confirming-robust-real-world-performance-of-avise-lupus
Ticker: XGN
Company: Exagen
Source: Exagen
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.exagen.com
## Summary

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical

## Article Body
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical
## Recent Company News
- 2026-06-25 13:46 EST — [Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus](https://biopharmsignal.com/news/XGN/exagen-announces-publication-of-systematic-review-confirming-robust-real-world-performance-of-avise-lupus) — Source: Exagen
- 2026-06-25 13:46 EST — [Exagen Inc. Reports First Quarter 2026 Results](https://biopharmsignal.com/news/XGN/exagen-inc-reports-first-quarter-2026-results) — Source: Exagen
- 2026-06-25 13:46 EST — [Exagen Inc. to Participate in Third Quarter Investor Conferences](https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-third-quarter-investor-conferences) — Source: Exagen
- 2026-06-25 13:46 EST — [Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025](https://biopharmsignal.com/news/XGN/exagen-inc-to-announce-third-quarter-2025-financial-results-on-november-4-2025) — Source: Exagen
- 2026-06-25 13:46 EST — [Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence](https://biopharmsignal.com/news/XGN/exagen-announces-acceptance-of-six-abstracts-at-2025-american-college-of-rheumatology-convergence) — Source: Exagen
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)